These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31519605)

  • 1. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Harada D; Takata K; Mori S; Kozuki T; Takechi Y; Moriki S; Asakura Y; Ohno T; Nogami N
    Anticancer Res; 2019 Sep; 39(9):4987-4993. PubMed ID: 31519605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
    Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
    Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
    Tanizaki S; Matsumoto K; Tamiya A; Taniguchi Y; Matsuda Y; Uchida J; Ueno K; Kawachi H; Tamiya M; Yanase T; Suzuki H; Okishio K
    Eur J Clin Pharmacol; 2023 Apr; 79(4):503-511. PubMed ID: 36773042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
    Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
    Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB
    Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
    Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
    Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M
    Front Oncol; 2023; 13():1247879. PubMed ID: 37731641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
    Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB
    Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study.
    Matsumoto K; Tamiya A; Inagaki Y; Taniguchi Y; Matsuda Y; Kawachi H; Tamiya M; Tanizaki S; Uchida J; Ueno K; Yanase T; Suzuki H; Atagi S
    J Geriatr Oncol; 2022 Mar; 13(2):207-213. PubMed ID: 34602370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer.
    Hamai K; Katsura R; Miyake S; Fujita S; Tada S; Hirakawa T; Ueno S; Tanimoto T; Ishikawa N
    Cancer Control; 2024; 31():10732748241274615. PubMed ID: 39120923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.
    Molife C; Hess LM; Cui ZL; Li XI; Beyrer J; Mahoui M; Oton AB
    Future Oncol; 2019 Sep; 15(25):2915-2931. PubMed ID: 30793926
    [No Abstract]   [Full Text] [Related]  

  • 18. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
    Kawachi H; Tamiya M; Matsumoto K; Tamiya A; Yanase T; Tanizaki S; Kumagai T
    Invest New Drugs; 2022 Jun; 40(3):634-642. PubMed ID: 35024985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M
    Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.